New and emerging therapies in psoriasis.

Craig L. Leonardi*, Kenneth B. Gordon

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

19 Scopus citations


This article discusses the scientific rationale for the use of cytokine inhibitors, including ustekinumab, an inhibitor of the interleukin (IL)-12 and IL-23 pathways in psoriasis. Also addressed are the efficacy and safety data for this agent, as well as for several emerging therapies that target other cytokine pathways in psoriasis: the IL-17 inhibitors secukinumab, ixekizumab, and brodalumab, the IL-23 blocker tildrakizumab, and the small-molecule kinase inhibitors apremilast (a phosphodiesterase-4 blocker) and tofacitinib (a Janus kinase inhibitor). 2014 published by Frontline Medical Communications.

Original languageEnglish (US)
Pages (from-to)S37-41
JournalSeminars in cutaneous medicine and surgery
Issue number2 Suppl 2
StatePublished - Mar 2014

ASJC Scopus subject areas

  • Surgery
  • Dermatology


Dive into the research topics of 'New and emerging therapies in psoriasis.'. Together they form a unique fingerprint.

Cite this